CommercialPrior AuthHigh impact
Pharmacy coverage changes
Harvard Pilgrim Health Care·Pulmonology, Allergy & Immunology, Dermatology +2 more·Pharmacy
Effective date
Sep 1, 2026
We identified it
Jul 2, 2026
Summary
Effective 9/1/2026, Point32Health is tightening prior authorization requirements for five biologic asthma/allergy medications (Dupixent, Fasenra, Nucala, Tezspire, Xolair) with stricter criteria including chart-confirmed diagnosis, disease severity documentation, concurrent therapy requirements, and minimum treatment durations. Additionally, certain non-preferred statin medications are moving to non-formulary status for Tufts Health RI Together plans, requiring prior authorization for coverage review.
Action Required
By August 31, 2026: (1) Billing and clinical teams must review and implement updated prior authorization protocols for Dupixent (dupilumab), Fasenra (benralizumab), Nucala (mepolizumab), Tezspire (tezepelumab-ekko), and Xolair (omalizumab) for Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, and Tufts Health Direct members. (2) Update prior auth request templates in billing system to require: chart-confirmed diagnosis documentation, disease severity assessment, documentation of concurrent therapies, and evidence of minimum non-biologic treatment duration before requesting biologics as add-on therapy. (3) For Tufts Health RI Together members: Update billing workflows to require prior authorization for ezetimibe/simvastatin, fluvastatin capsule/ER, pitavastatin, zypitamag, FloLipid suspension, and Ezallor sprinkle capsule. Continue processing generic atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin without prior auth. (4) Providers should update encounter templates to capture required clinical documentation elements. (5) Train billing staff on new separation between failure of treatment alternatives vs. add-on therapy requests. Claims submitted without proper documentation will be denied or delayed pending additional information.